Lina Wu

Prof. Lina Wu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2020 in The Journal of Physical Chemistry Letters
Verified
Journal Article
Closed access
ZWZhijiang Wang
Zhijiang Wang
QYQi Yuan
Qi Yuan
JSJingjing Shan
Jingjing Shan
ZJZhaohua Jiang
Zhaohua Jiang
Ping XuPing Xu
Ping Xu
WGWILLIAM Andrew GODDARD
WILLIAM Andrew GODDARD

18 August 2023 in Advanced Science
Verified
Journal Article
Open access
CNChaoqun Nie
Chaoqun Nie
RARong A
Rong A
JWJing Wang
Jing Wang
SPShuang Pan
Shuang Pan
RZRentong Zou
Rentong Zou
WYWei Yang
Wei Yang
Hydrogen gas is recently proven to have anti‐oxidative and anti‐inflammation effects on ischemia‐reperfusion injury. However, the efficacy of hydrogen therapy is limited by the efficiency of hydrogen storage, targeted delivery, and controlled release. In this study, H2‐PFOB nanoemulsions (NEs) is developed with high hydrogen loading capacity for targeted ischemic myocardium precision therapy. The hydrogen‐carrying capacity of H2‐PFOB NEs is determined by gas chromatography and microelectrode methods. Positive uptake of H2‐PFOB NEs in ischemia‐reperfusion myocardium and the influence of hydrogen on 19F‐MR signal are quantitatively visualized using a 9.4T MR imaging system. The biological therapeutic effects of H2‐PFOB NEs are examined on a myocardial ischemia‐reperfusion injury mouse model. The results illustrated that the developed H2‐PFOB NEs can efficaciously achieve specific infiltration into ischemic myocardium and exhibit excellent antioxidant and anti‐inflammatory properties on myocardial ischemia‐reperfusion injury, which can be dynamically visualized by 19F‐MR imaging system. Moreover, hydrogen burst release induced by low‐intensity focused ultrasound (LIFU) irradiation further promotes the therapeutic effect of H2‐PFOB NEs with a favorable biosafety profile. In this study, the potential therapeutic effects of H2‐PFOB NEs is fully unfolded, which may hold great potential for future hydrogen‐based precision therapeutic applications tailored to ischemia‐reperfusion injury.

1 December 2022 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
YSYige Sun
Yige Sun
JYJie Yang
Jie Yang
YLYingbo Li
Yingbo Li
JLJing Luo
Jing Luo
JSJiemei Sun
Jiemei Sun
XSXilin Sun
Xilin Sun
Background: Non-small cell lung cancer (NSCLC) patients with primary tumors and liver metastases have substantially reduced survival. Since mesenchymal-epithelial transition factor (MET) plays a significant role in the molecular mechanisms of advanced NSCLC, small molecule MET inhibitor capmatinib (INC280) hold promise for clinically NSCLC treatment. However, the major obstacles of MET-targeted therapy are poor drug solubility and off-tumor effects, even oral high-dosing regimens cannot significantly increase the therapeutic drug concentration in primary and metastatic NSCLC. Methods: We developed a multirooted delivery system INC280-PFCE nanoparticles (NPs) by loading INC280 into perfluoro-15-crown-5-ether for improving MET-targeted therapy. Biodistribution and anti-MET/antimetastatic effects of NPs were validated in orthotopic NSCLC and NSCLC liver metastasis models in a single low-dose. The efficacy of INC280-PFCE NPs was also explored in human NSCLC specimens. Results: INC280-PFCE NPs exhibited excellent antitumor ability in vitro. In orthotopic NSCLC models, sustained release and prolonged retention behaviors of INC280-PFCE NPs within tumors could be visualized in real-time by 19F magnetic resonance imaging (19F-MRI), and single pulmonary administration of NPs showed more significant tumor growth inhibition than oral administration of free INC280 at a tenfold higher dose. Furthermore, a single low-dose INC280-PFCE NPs administered intravenously suppressed widespread dissemination of liver metastasis without systemic toxicity. Finally, we verified the clinical translation potential of INC280-PFCE NPs in human NSCLC specimens. Conclusions: These results demonstrated high anti-MET/antimetastatic efficacies, real-time MRI visualization and high biocompatibility of NPs after a single low-dose.

1 April 2023 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
DLDaoshuang Li
Daoshuang Li
JYJie Yang
Jie Yang
ZXZuoyu Xu
Zuoyu Xu
YLYingbo Li
Yingbo Li
YSYige Sun
Yige Sun
XSXilin Sun
Xilin Sun
Purpose: Precisely detecting colorectal liver metastases (CLMs), the leading cause of colorectal cancer-associated mortality, is extremely important. 1H MRI with high soft tissue resolution plays a key role in the diagnosing liver lesions; however, precise detecting CLMs by 1H MRI is a great challenge due to the limited sensitivity. Even though contrast agents may improve the sensitivity, due to their short half-life, repeated injections are required to monitor the changes of CLMs. Herein, we synthesized c-Met-targeting peptide-functionalized perfluoro-15-crown-5-ether nanoparticles (AH111972-PFCE NPs), for highly sensitive and early diagnosis of small CLMs. Methods: The size, morphology and optimal properties of the AH111972-PFCE NPs were characterized. c-Met specificity of the AH111972-PFCE NPs was validated by in vitro experiment and in vivo 19F MRI study in the subcutaneous tumor murine model. The molecular imaging practicability and long tumor retention of the AH111972-PFCE NPs were evaluated in the liver metastases mouse model. The biocompatibility of the AH111972-PFCE NPs was assessed by toxicity study. Results: AH111972-PFCE NPs with regular shape have particle size of 89.3 ± 17.8 nm. The AH111972-PFCE NPs exhibit high specificity, strong c-Met-targeting ability, and precise detection capability of CLMs, especially small or ill-defined fused metastases in 1H MRI. Moreover, AH111972-PFCE NPs could be ultralong retained in metastatic liver tumors for at least 7 days, which is conductive to the implementation of continuous therapeutic efficacy monitoring. The NPs with minimal side effects and good biocompatibility are cleared mainly via the spleen and liver. Conclusion: The c-Met targeting and ultralong tumor retention of AH111972-PFCE NPs will contribute to increasing therapeutic agent accumulation in metastatic sites, laying a foundation for CLMs diagnosis and further c-Met targeted treatment integration. This work provides a promising nanoplatform for the future clinical application to patients with CLMs.

22 March 2023 in Nano Letters
Verified
Journal Article
Closed access
HWHongbin Wang
Hongbin Wang
XLXiaona Li
Xiaona Li
JWJing Wang
Jing Wang
JWJiannan Wang
Jiannan Wang
HZHongyan Zou
Hongyan Zou
XSXilin Sun
Xilin Sun

29 July 2020 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Closed access
PDF file
LWLina Wu
Lina Wu
HZHongyan Zou
Hongyan Zou
HWHongbin Wang
Hongbin Wang
SZSihang Zhang
Sihang Zhang
SLShuang Liu
Shuang Liu
XSXilin Sun
Xilin Sun